Skip to main content

ORIGINAL RESEARCH article

Front. Pediatr.
Sec. Pediatric Neurology
Volume 12 - 2024 | doi: 10.3389/fped.2024.1388008

Exploratory analysis of high-dose corticosteroid therapy on epileptic encephalopathy with spike-and-wave activation in sleep (EE-SWAS)

Provisionally accepted
Hu Xiaoyue Hu Xiaoyue 1,2Tang Hongwei Tang Hongwei 1,2*Wang Jianbiao Wang Jianbiao 1,2*Ma Jingbo Ma Jingbo 1,2*Hua Ying Hua Ying 1,2*
  • 1 Wuxi Children’s Hospital, Wuxi, China
  • 2 Jiangnan University, Wuxi, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Objective: This study aims to evaluate the therapeutic efficacy of highdose corticosteroid therapy in children diagnosed with epileptic encephalopathy with spike-and-wave activation in sleep (EE-SWAS), investigate associated clinical indicators influencing treatment outcomes, and establish a predictive model for recurrence.Children diagnosed with EE-SWAS who received high-dose corticosteroid therapy were categorized into responder group and nonresponder group. Data on clinical parameters, electroencephalogram (EEG) features, and serum cytokine levels were collected. Six months post-treatment, the effectively treated children were further stratified into recurrence and non-recurrence groups. Risk factors for poor outcomes following corticosteroid therapy were identified using univariate analysis.Multivariate logistic regression analysis was then employed to determine independent factors influencing the recurrence of corticosteroid therapy, which facilitated the development of a predictive model.Results:The study included 48 children, with 33 cases in the responder group (effective rate=68.8%) and 15 cases in the non-responder group.The responder group exhibited an older onset age of electrical status epilepticus in sleep (ESES) and higher proportions of combined benzodiazepines (BZDs) use (P<0.05). Among those responding to corticosteroid therapy, 11 cases experienced a recurrence (recurrence rate=33.3%), while 22 cases did not. Significant differences were observed between the two groups concerning age of seizure onset, age of ESES onset, seizure frequency, atypical presentations, and concomitant frontal lobe discharges (all P<0.05). Concomitant frontal lobe discharges and an earlier age of seizure onset were identified as risk factors for ESES recurrence following corticosteroid therapy. The predictive model was formulated as Logit(P) = 2.35 × presence of frontal lobe discharges -0.802 × age of seizure onset + 2.457. The Area Under the Curve (AUC) of Receiver Operating Characteristics (ROC) was 0.93, with sensitivity and specificity at 100% and 77.3%, respectively.High-dose corticosteroid therapy for EE-SWAS exhibited a high effective rate as well as a notable recurrence rate. Onset age of ESES and combined benzodiazepines usage correlated with therapeutic efficacy.Seizure onset age and the presence of frontal lobe discharges may hold predictive value for recurrence following corticosteroid therapy.

    Keywords: EE-SWAS, ESES, Corticosteroid therapy, influencing factor, Children, predictive model

    Received: 19 Feb 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Xiaoyue, Hongwei, Jianbiao, Jingbo and Ying. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Tang Hongwei, Wuxi Children’s Hospital, Wuxi, China
    Wang Jianbiao, Wuxi Children’s Hospital, Wuxi, China
    Ma Jingbo, Wuxi Children’s Hospital, Wuxi, China
    Hua Ying, Wuxi Children’s Hospital, Wuxi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.